Drug · CHEMBL185
Comparisons in its trials378
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 378
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 205 of 2,400 | 247 of 2,404 | 4,804 | NCT01358877 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | 792 of 2,364 | 686 of 2,405 | 4,769 | NCT01358877 | Trial comparisons |
| Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): Incidence of Adverse Events for Each Treatment | 416 of 2,227 | 429 of 2,219 | 4,446 | NCT02135419 | Trial comparisons |
| Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): deaths from any cause | 55 of 2,227 | 48 of 2,219 | 4,446 | NCT02135419 | Trial comparisons |
| Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): serious adverse events | 370 of 2,227 | 375 of 2,219 | 4,446 | NCT02135419 | Trial comparisons |
| Adriamycin + Cyclophosphamide vs Fluorouracil + Epirubicin + Cyclophosphamide: serious adverse events | 12 of 1,351 | 26 of 1,337 | 2,688 | NCT00087178 | Trial comparisons |
| Oxaliplatin + Leucovorin + 5-Fluorouracil vs Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab: serious adverse events | 81 of 1,326 | 270 of 1,334 | 2,660 | NCT00096278 | Trial comparisons |
| Capecitabine vs 5-Fluorouracil + Leucovorin: Relapse-Free Survival | 677 of 1,004 | 621 of 983 | 1,987 | NCT00009737 | Trial comparisons |
| Capecitabine vs 5-Fluorouracil + Leucovorin: Disease-free Survival | 656 of 1,004 | 603 of 983 | 1,987 | NCT00009737 | Trial comparisons |
| Capecitabine vs 5-Fluorouracil + Leucovorin: Overall Survival | 804 of 1,004 | 756 of 983 | 1,987 | NCT00009737 | Trial comparisons |
| Capecitabine vs 5-Fluorouracil + Leucovorin: serious adverse events | 181 of 995 | 182 of 974 | 1,969 | NCT00009737 | Trial comparisons |
| Arm A: FAC vs Arm B: FAC-wP: Overall Survival (OS) Event | 40 of 974 | 31 of 951 | 1,925 | NCT00129389 | Trial comparisons |
| Arm A: FAC vs Arm B: FAC-wP: deaths from any cause | 40 of 974 | 31 of 951 | 1,925 | NCT00129389 | Trial comparisons |
| Arm A: FAC vs Arm B: FAC-wP: Disease-free Survival (DFS) Event | 98 of 974 | 71 of 951 | 1,925 | NCT00129389 | Trial comparisons |
| Arm A: FAC vs Arm B: FAC-wP: serious adverse events | 60 of 974 | 61 of 951 | 1,925 | NCT00129389 | Trial comparisons |
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE) | 267 of 785 | 206 of 787 | 1,572 | NCT03675737 | Trial comparisons |
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Experienced an Adverse Event (AE) | 776 of 785 | 771 of 787 | 1,572 | NCT03675737 | Trial comparisons |
| Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: deaths from any cause | 507 of 624 | 499 of 629 | 1,253 | NCT02753127 | Trial comparisons |
| Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: serious adverse events | 234 of 622 | 201 of 610 | 1,232 | NCT02753127 | Trial comparisons |
| Cetuximab Plus FOLFIRI vs FOLFIRI Alone: Safety - Number of Patients Experiencing Any Adverse Event | 599 of 600 | 597 of 602 | 1,202 | NCT00154102 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL185/comparisons